A 2012 study of patients with low-tumor-burden follicular lymphoma showed that the 4-year freedom from treatment failure rate ...

As a lymphoma survivor, I struggle with the positivity trap — sometimes, I just want my fears validated instead of being ...

Follicular lymphoma is a diverse disease, both biologically and clinically. Patients may present with indolent, asymptomatic disease or more aggressive, symptomatic disease with high tumor burden.

The FDA granted Crispr Therapeutics (CRSP) orphan status for its treatment of follicular lymphoma.Don't Miss Our End of Quarter Offers: ...

Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window Follicular ...

China’s National Medical Products Administration (NMPA) has granted conditional approval for Hutchmed’s Tazverik (tazemetostat) to treat adults with relapsed or refractory (R/R) follicular lymphoma ...

Cancer experiences are highly individualized, even among patients with the same type of cancer, challenging common stereotypes. Follicular lymphoma, a blood cancer, often lacks a single tumor, ...

The author of the ‘Leonard List’ that highlights emerging hematologic research to be presented at annual ASH meetings is also ...

Novartis' CAR-T Kymriah has become the first therapy in the category to be approved for the treatment of relapsed/refractory follicular lymphoma, ahead of Gilead Sciences' rival Yescarta.

TAZVERIK ® is a registered trademark of Epizyme Inc., an Ipsen company.